FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0287							
Esti	mated average	burden					
hou	rs per response	: 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STAAB THOMAS R II				2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2011								Senior Vice President and CFO					
(Street) DURHA (City)	AM NC 27703 (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Ta	ıble I - Non-	Derivat	ive S	ecuritie	s Acc	nuired. I	Disr	nosed o	f. or Bei	neficial	lv Ow	ned				
1. Title of Security (Instr. 3) 2. T			2. Transac Date			ned n Date,	a. 3. 4. Securities Acquir Disposed Of (D) (Instruction Code (Instr.)		ed (A) or	5. 15) Se Be	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	nt (A) or (D)		Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock ⁽¹⁾			07/01/2	1/2011		A		25,000 A		\$(25,000			D			
			Table II - D (e					uired, Di , option:	•	,			Own	ed		,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		Expiration Date	Title	Amount or Number of Share	s		Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$3.78	07/01/2011		A		200,000		07/01/2012 ⁽	2) 0	7/01/2021	Common Stock	200,00	0	\$0	200,0	00	D	

Explanation of Responses:

- 1. Restricted stock award. Will vest on the first anniversary of the date of grant, subject to continued employment on such vesting date.
- 2. Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane Barnes, by power of attorney

07/08/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.